An orphan designation may add value to a product by potentially increasing stock value, increasing the company visibility, and initiating early interactions with Health Authorities. However, seeking an orphan designation too early has its disadvantages, including public disclosure of regulatory strategy, product positioning, and risking a premature application with a following rejection due to insufficient data. As a result, when to submit an ODD is subject to particular consideration. This paper explores how to optimize this process.
Explore related content and topics
White Paper
Data Sharing & Anonymization - Current Overview of Data Sharing within Clinical Trial Transparency
Clinical trial transparency has emerged in recent years as a key function within pharmaceutical and academic organizations. Although trial…
White Paper
Pediatric Product Development Plan
Development of the Pediatric Study Plan (PSP) for the United States Food and Drug Administration and the Pediatric Investigation Plan (PIP) for the…
Page
Global Regulatory Affairs
PRA’s Global Regulatory Affairs (GRA) group brings more than 20 years’ experience navigating the complex regulatory environment. We leverage our…